Academic scientists and external organisations will gather at the Clinical Research Centre in Malmö on September 26 to identify projects that can be developed to products or services for diabetes patients or for people at risk of developing diabetes.
SWElife aims to support projects in which academia, industry, and health care collaborate to develop more efficient structures and processes for national use and further development of existing research infrastructure within the diabetes field. (e.g. technology platforms, testbeds, biobanks, the Diabetes Register and other types of data sources, the Diabetes Portal, SciLifeLab and Clinical Studies Sweden).
For researchers involved in signalling pathways and identification of receptors and with limited expertise in Drug Discovery and Medicinal Chemistry; developing compounds targeting identified pathways has been a major hurdle both funding-wise - too late for research funding and too early for commercial investment - and competence-wise.
The focus group for diabetes connects Life Science companies in Skåne in different stages with academia and the health care system and was started as an inititiative between Lund University Diabetes Center and Medeon Life Science incubator. The aim of the group is to promote the Life Science sector and research utilization in the South of Sweden. The focus group has been running for a year and will continue and expand to include companies also from Denmark. Participants are Rubin Medicals, Hemocure, Novo Nordisk, Lantmännen AB, Vibriosense, Menarini Diagnostics and various smaller start-up companies. If interested in joining please contact Innovation Manager Annie George Chandy (email@example.com).
Last updated: June 14, 2016
Website contact: LUDC webteam